Literature DB >> 8343277

Vinca alkaloids: anti-vascular effects in a murine tumour.

S A Hill1, S J Lonergan, J Denekamp, D J Chaplin.   

Abstract

We have investigated the blood flow modifying effects of the vinca alkaloids, vincristine and vinblastine in the murine carcinoma CaNT. Vinblastine at doses of 7.5 or 10 mg/kg induced profound and chronic reductions in tumour blood flow as measured by 86RbCl extraction. Following the maximum tolerated dose of 10 mg/kg, blood flow was reduced to 10% of pretreatment values after 2 h and remained below 20% of pretreatment values 24 h after drug administration. These findings are consistent with the early induction of necrosis by vinblastine and suggest that vascular-mediated cell death may account for a large part of the 11 day growth delay induced by this drug dose. In contrast to the large reductions in tumour blood flow, in skin, kidney, liver and muscle, blood flow reductions did not, at any time examined, exceed 40%. In all the normal tissues studied, blood flow had fully recovered by 6 h after vinblastine administration. Similar results, albeit less pronounced, have been obtained with vincristine at the maximum tolerated dose of 3 mg/kg. The results clearly show that both vinblastine and vincristine can induce, with some selectivity, a dramatic and prolonged reduction in tumour blood flow and that this may contribute to the anti-tumour effects against the CaNT tumour.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8343277     DOI: 10.1016/0959-8049(93)90082-q

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  30 in total

Review 1.  Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.

Authors:  Nicholas F Dybdal-Hargreaves; April L Risinger; Susan L Mooberry
Journal:  Clin Cancer Res       Date:  2015-04-02       Impact factor: 12.531

Review 2.  Antivascular actions of microtubule-binding drugs.

Authors:  Edward L Schwartz
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 3.  Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.

Authors:  Chryso Kanthou; Gillian M Tozer
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

4.  Schedule-dependent interaction between vinblastine and irradiation in experimental sarcoma.

Authors:  Maja Cemazar; Tanja Dolinsek; Tina Kosjek; Bostjan Markelc; Gregor Sersa; Veronika Kloboves; Primoz Strojan
Journal:  Strahlenther Onkol       Date:  2014-03-11       Impact factor: 3.621

5.  Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.

Authors:  D J Chaplin; G R Pettit; C S Parkins; S A Hill
Journal:  Br J Cancer Suppl       Date:  1996-07

6.  Total synthesis of vinblastine, vincristine, related natural products, and key structural analogues.

Authors:  Hayato Ishikawa; David A Colby; Shigeki Seto; Porino Va; Annie Tam; Hiroyuki Kakei; Thomas J Rayl; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2009-04-08       Impact factor: 15.419

7.  Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation.

Authors:  Hiroaki Tanaka; Hironori Matsushima; Akiko Nishibu; Björn E Clausen; Akira Takashima
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

8.  The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death.

Authors:  Chryso Kanthou; Olga Greco; Anna Stratford; Ian Cook; Richard Knight; Omar Benzakour; Gillian Tozer
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

9.  5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.

Authors:  G J S Rustin; C Bradley; S Galbraith; M Stratford; P Loadman; S Waller; K Bellenger; L Gumbrell; L Folkes; G Halbert
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Authors:  K Hori; S Saito; K Kubota
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.